US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Nasdaq Biotechnology ETF

34.75

+0.38001.11%

Post-market: 34.750.00000.00%16:10 EDT

Volume:100.22K

Turnover:3.46M

Market Cap:107.73M

PE:- -

High:34.80

Open:34.53

Low:34.07

Close:34.37

52wk High:36.84

52wk Low:25.00

Shares:3.10M

Float Shares:3.10M

Volume Ratio:1.32

T/O Rate:3.23%

Dividend:0.39

Dividend Rate:1.13%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Sanofi, Regeneron Expand Tie-up with $8 Billion Drug-Development Deal, Settle Legal Dispute

Regeneron, Sanofi Expand Antibody Alliance with USD 1 Billion Upfront Payment

Sanofi, Regeneron Expand Antibody Alliance in Long-Acting Immunology Programs for USD 1 Billion Upfront

Sanofi - Companies to Equally Share Development and Commercialization Costs, as Well as Any Future Profits

THOMSON REUTERS

Sanofi - and Regeneron Settle Prior Collaboration-Related Litigation

THOMSON REUTERS

Sanofi - Regeneron May Include Sanofi's Lunsekimig Therapy After Phase 3 Studies

THOMSON REUTERS

Sanofi - Regeneron to Receive $1 Bln Upfront with Potential for up to an Additional $7 Bln in Future Milestone Payments

THOMSON REUTERS

Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Paramount Names Kreiz as Co-CEO as Warner Bros. Deal Nears Completion

Regeneron Drug Halves Muscle Loss in Combination with Novo's Semaglutide in Trial

Gilead Sciences Inc. Stock Underperforms Wednesday When Compared to Competitors

Moderna Inc. Stock Sheds 5.4%, Underperforms Peers

Regeneron Links 2026 CEO, CSO PSU Awards to FDA Filings, Approvals and New-Product Revenue Targets Through 2035

Gilead put volume heavy and directionally bearish

Lilly's Closely Watched Obesity Combination Therapy Shows Greater Weight Loss in Mid-Stage Trial

Regeneron’s ALN-F1202 Safety Trial Marks a Quiet but Important Pipeline Milestone

Pre-Holiday Gains: Can This Strong Sector Keep Rising After the Break?

China Pharma Sector Divergence Deepens as Innovative Drug Leaders Ride BD Second Growth Curve

MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/IBBQ/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.75,"timestamp":1791230400000,"preClose":34.37,"halted":0,"volume":100218,"hourTrading":{"tag":"盘后","latestPrice":34.75,"preClose":34.75,"latestTime":"16:10 EDT","volume":153,"amount":5316.75,"timestamp":1791231005662,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.011056153622345143,"floatShares":3100001,"shares":3100001,"eps":0,"marketStatus":"Post-Mkt","change":0.38,"latestTime":"10-05 16:13:30 EDT","open":34.53,"high":34.8,"low":34.07,"amount":3459436.66707,"amplitude":0.021239,"askPrice":35.09,"askSize":8500,"bidPrice":34.33,"bidSize":8700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791244800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":34.37,"sharesOutstanding":2520001,"nav":34.4248,"aum":106440372.14,"dividendRate":0.011275,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.37,"preClose":34.37,"latestTime":"07:35 EDT","volume":1,"amount":34.37,"timestamp":1791200149459,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":34.75,"preClose":34.75,"latestTime":"16:10 EDT","volume":153,"amount":5316.75,"timestamp":1791231005662,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.318197,"impliedVol":0.073,"impliedVolPercentile":0.1833},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":3100001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.318197,"shares":3100001,"dividePrice":0.3918,"high":34.8,"amplitude":0.021239,"preClose":34.37,"low":34.07,"week52Low":25,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.75,"committee":0.011628,"eps":0,"divideRate":0.011275,"volume":100218,"delay":0,"ttmEps":0,"open":34.53,"prevYearClose":28.3962,"prevWeekClose":34.37,"prevMonthClose":35.14,"prevQuarterClose":35.14,"fiveDayClose":35.28,"twentyDayClose":36.05,"sixtyDayClose":33.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"IBBQ","amount":0.23037,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-25"},{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672734089","title":"Sanofi, Regeneron Expand Tie-up with $8 Billion Drug-Development Deal, Settle Legal Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2672734089","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672734089?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:40","pubTimestamp":1790833252,"startTime":"0","endTime":"0","summary":"UPDATE 4-Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal disputeOct 1 (Reuters)-SanofiSASY.PAand RegeneronREGN.Osaid on Thursday they will develop four new drugs to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nL6N45N09P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","IBBQ","TBXU","LU0889565916.HKD","LU0823416689.USD","LU0320765992.SGD","BBH","LU0109394709.USD","LU2106854487.HKD","LU1974910355.USD","LU2362541513.USD","REGN","LU0882574055.USD","LU0058720904.USD","IBB","BK4585","LU2089984988.USD","LU2468319806.SGD","LU0823434740.USD","LU2023250504.SGD","BK4588","LU2362540622.SGD","LU0289739699.SGD","LU0053666078.USD","BK4139","LU0823434583.USD","LU1917777945.USD","LU2237438978.USD","LU2362541273.HKD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672734581","title":"Regeneron, Sanofi Expand Antibody Alliance with USD 1 Billion Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2672734581","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672734581?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:01","pubTimestamp":1790830918,"startTime":"0","endTime":"0","summary":"Regeneron, Sanofi expand antibody alliance with USD 1 billion upfront paymentRegeneron expanded its immunology alliance with Sanofi to co-develop and co-commercialize four next-generation, long-acting","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL5hDHkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4112","SG9999014039.USD","LU2324357040.USD","LU0823434583.USD","LU0058720904.USD","LU2362540622.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU1917777945.USD","LU0320765992.SGD","LU0109394709.USD","IE00BN0W2W23.USD","IBB","IE00BGHQF748.EUR","BK4139","LU2362541273.HKD","LU2468319806.SGD","LU0314104364.USD","IE00BQXX3C00.GBP","LU2210150020.SGD","TBXU","SG9999014021.USD","LU0053666078.USD","LU2089984988.USD","LU0114720955.EUR","IBBQ","NDAQ","IE00BN0W2V16.EUR","LU1974910355.USD","LU2210149790.SGD","LU0289739699.SGD","LU2106854487.HKD","SG9999014005.SGD","LU2362541513.USD","BK4588","LU0823434740.USD","LU0882574055.USD","IE00BQXX3F31.USD","LU2095319765.USD","LU0823416689.USD","BCDF","BK4585","BBH","REGN","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","LU2237438978.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672533734","title":"Sanofi, Regeneron Expand Antibody Alliance in Long-Acting Immunology Programs for USD 1 Billion Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2672533734","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672533734?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:01","pubTimestamp":1790830877,"startTime":"0","endTime":"0","summary":"Sanofi, Regeneron expand antibody alliance in long-acting immunology programs for USD 1 billion upfrontSanofi expanded its global antibody alliance with Regeneron to add four next-generation, long-act","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDLbTWmXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU0114720955.EUR","LU0823434740.USD","LU2095319765.USD","LU2362540622.SGD","LU0889565916.HKD","LU2362541273.HKD","BBH","BK4139","SG9999014039.USD","LU0320765992.SGD","IE00BQXX3D17.EUR","LU2210149790.SGD","LU0053666078.USD","LU0058720904.USD","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","LU0882574055.USD","BK4112","IE00B3QW5Z07.USD","LU1974910355.USD","LU2089984988.USD","BCDF","LU2106854487.HKD","IE00B64PRP62.GBP","LU2324357040.USD","SG9999014021.USD","TBXU","IBB","LU2362541513.USD","IBBQ","NDAQ","LU0823416689.USD","IE00BN0W2T93.GBP","BK4588","LU1917777945.USD","BK4585","LU0314104364.USD","LU2023250504.SGD","LU0289739699.SGD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BKPKM429.USD","LU0109394709.USD","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","LU0823434583.USD","LU2237438978.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672734593","title":"Sanofi - Companies to Equally Share Development and Commercialization Costs, as Well as Any Future Profits","url":"https://stock-news.laohu8.com/highlight/detail?id=2672734593","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672734593?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:00","pubTimestamp":1790830810,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N05O:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU2237438978.USD","LU0823416689.USD","LU1974910355.USD","BBH","LU2468319806.SGD","LU2106854487.HKD","LU2023250504.SGD","LU0823434583.USD","BK4585","BK4588","REGN","IBB","LU2362541273.HKD","LU0289739699.SGD","LU0882574055.USD","LU0823434740.USD","LU1917777945.USD","IBBQ","LU0058720904.USD","LU0320765992.SGD","LU2324357040.USD","TBXU","BK4139","LU0114720955.EUR","LU2362541513.USD","LU2362540622.SGD","LU0053666078.USD","LU2089984988.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672573435","title":"Sanofi - and Regeneron Settle Prior Collaboration-Related Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2672573435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672573435?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:00","pubTimestamp":1790830810,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N05O:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REGN","LU0114720955.EUR","LU0823434740.USD","LU2362540622.SGD","LU0889565916.HKD","LU2362541273.HKD","BBH","BK4139","LU0320765992.SGD","LU0053666078.USD","LU0058720904.USD","LU0882574055.USD","LU1974910355.USD","LU2089984988.USD","LU2106854487.HKD","LU2324357040.USD","TBXU","IBB","LU2362541513.USD","IBBQ","LU0823416689.USD","BK4588","LU1917777945.USD","BK4585","LU2023250504.SGD","LU0289739699.SGD","LU0109394709.USD","LU0823434583.USD","LU2237438978.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672343697","title":"Sanofi - Regeneron May Include Sanofi's Lunsekimig Therapy After Phase 3 Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2672343697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672343697?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:00","pubTimestamp":1790830810,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N05O:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2362541513.USD","LU2089984988.USD","BK4588","BBH","LU0823416689.USD","TBXU","LU2023250504.SGD","LU0109394709.USD","LU2324357040.USD","LU1974910355.USD","LU2362541273.HKD","BK4585","LU0823434583.USD","LU2468319806.SGD","LU2362540622.SGD","BK4139","IBB","LU0889565916.HKD","LU0823434740.USD","IBBQ","LU0289739699.SGD","LU2237438978.USD","LU0320765992.SGD","LU0882574055.USD","LU0058720904.USD","LU0114720955.EUR","LU2106854487.HKD","REGN","LU0053666078.USD","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672734350","title":"Sanofi - Regeneron to Receive $1 Bln Upfront with Potential for up to an Additional $7 Bln in Future Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2672734350","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672734350?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:00","pubTimestamp":1790830808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45M1B3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBH","LU0320765992.SGD","LU2106854487.HKD","LU2362540622.SGD","LU2324357040.USD","LU0889565916.HKD","BK4585","LU0114720955.EUR","LU1974910355.USD","LU2362541513.USD","REGN","LU2023250504.SGD","LU0058720904.USD","LU0823416689.USD","LU2362541273.HKD","IBB","LU0053666078.USD","LU0109394709.USD","IBBQ","BK4588","LU0289739699.SGD","LU0882574055.USD","LU2089984988.USD","LU0823434583.USD","LU2468319806.SGD","TBXU","LU0823434740.USD","LU1917777945.USD","LU2237438978.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672983731","title":"Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2672983731","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672983731?lang=en_us&edition=fundamental","pubTime":"2026-10-01 12:18","pubTimestamp":1790828280,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Limited ( ($AU:ALA) ) has provided an announcement. Arovella Therapeutics is advancing an iNKT cell therapy platform aimed at...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arovella-nears-first-patient-dosing-in-pivotal-ala-101-cell-therapy-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arovella-nears-first-patient-dosing-in-pivotal-ala-101-cell-therapy-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","IBBQ","CNCR","GNOM","LABX","ALA","LFSC","TBXU","BK4588","BK4585","IBB","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672273391","title":"The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind","url":"https://stock-news.laohu8.com/highlight/detail?id=2672273391","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672273391?lang=en_us&edition=fundamental","pubTime":"2026-10-01 08:00","pubTimestamp":1790812800,"startTime":"0","endTime":"0","summary":"For as long as drugmakers have been testing weight-loss drugs, the question has been: How much weight do people lose?Now it is changing to: What kind of weight are they losing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","IE00BK4W5L77.USD","LU0106261372.USD","LU0354030438.USD","BK4139","LU1623119135.USD","LU2089984988.USD","ILDR","IHE","IBB","BK4534","IE00BJT1NW94.SGD","LU2237443978.SGD","MHIP","PPH","IE00BK4W5M84.HKD","LU1551013425.SGD","IE00BFTCPJ56.SGD","LU2456880835.USD","LU2462157665.USD","LU0683600562.USD","LU2462591350.SGD","LU1691799644.USD","LU1720051108.HKD","ELIS","LU0234572021.USD","LU1868836591.USD","BBH","LU0889565916.HKD","MEDX","LU2756315318.SGD","LU0174119429.USD","LU0320765992.SGD","LU2106854487.HKD","SGXZ51526630.SGD","LU2361044949.HKD","LU0061475181.USD","LU2213496289.HKD","CURE","IE00BKPKM429.USD","LLII","LU1814569148.SGD","NVOC","SG9999015986.USD","IYH","LU0385154629.USD","LU0640476718.USD","LU2112291526.USD","SG9999014880.SGD","LU2089284900.SGD","IE00B7KXQ091.USD","SG9999018865.SGD","LU0122379950.USD","BK4533","LU0114720955.EUR","LU2211815571.USD","LU2089283258.USD","LLY","LU1804176565.USD","LU2491050071.SGD","OZEM","IE00B1BXHZ80.USD","LU2491049909.HKD","LU0353189763.USD","BK4588","LU0882574055.USD","LU1720051017.SGD","IE00BJJMRY28.SGD","LU0109391861.USD","IXJ","WDNA","LU0820561818.USD","LU2471134952.CNY","BK4599","LU1064131342.USD","LU1983299246.USD","LU2491050154.USD","LU2756315664.SGD","IBBQ","LU0256863902.USD","LU0672654240.SGD","LU0210536198.USD","LU1267930730.SGD","LU2471134796.USD","LU2552382058.USD","LU1868836757.USD","IE00BJJMRX11.SGD","SGXZ31699556.SGD","LU1366192091.USD","LU0787776722.HKD","LU2168564065.EUR","LU1712237335.SGD","LU0323591593.USD","LU2602419157.SGD","LU0096364046.USD","LLYX","LU0289739699.SGD","LU0097036916.USD","LU0345770993.USD","LU0345770308.USD","LU0353189680.USD","LU0256863811.USD","LLYZ","LU1023059063.AUD","LU1093756325.SGD","BK4516","BK4585","LU0058720904.USD","LU0198837287.USD","LU0432979614.USD","LU2237443382.USD","LU2362541513.USD","SG9999001176.USD","LU2237443465.HKD","LU0154236417.USD","LU0689472784.USD","LU2471134523.USD","BK4532","IE0004445015.USD","LU0823434583.USD","LU0823434740.USD","LU2111349929.HKD","LU0238689110.USD","LU2168564149.EUR","SGXZ99366536.SGD","LU0320765059.SGD","LU0964807845.USD","LU2237438978.USD","LU2746668461.USD","LU2552382215.SGD","CANC","LU0109394709.USD","IE00B2B36J28.USD","LU1323610961.USD","LU2361045086.USD","SGXZ81514606.USD","TMED","LU2023251221.USD","LU0820561909.HKD","SG9999014898.SGD","LU0417517546.SGD","LU0053666078.USD","VHT","LU2028103732.USD","AGNG","LU1061106388.HKD","SG9999001176.SGD","FHLC","TRUH","NVOH","LU0158827948.USD","ELIL","LU0158827781.USD","LU2237443622.USD","LU2362541273.HKD","LU1629891620.HKD","LU2108987350.USD","NVOX","LU0943347566.SGD","LU2468319806.SGD","IE00BN29S564.USD","IE00BZ1G4Q59.USD","LU2271345857.HKD","LU2063271972.USD","LU2361044865.SGD","HRTS","LU2362540622.SGD","SG9999015952.SGD","SG9999017495.SGD","IE00B1XK9C88.USD","SG9999014906.USD","SGXZ57979304.SGD","LU2461242641.AUD","LU2552382132.HKD","LU0316494557.USD","LU2023250504.SGD","NVO","REGN","IE00B4JS1V06.HKD","IE0002141913.USD","PJP","LU0471298694.HKD","LU1127390331.HKD","IE0009355771.USD","LU1280957306.USD","LU1035775433.USD","SG9999015978.USD","LU2023250330.USD","TBXU","IE0001KFT4U8.USD","IE0005OL40V9.USD","GB00BDT5M118.USD","LU0456855351.SGD","LU0823416689.USD","LU1057294990.SGD","SG9999018857.SGD","LU1868836914.USD","LU1979441026.SGD","LU2746668974.SGD","LU1988902786.USD","LU1989771016.USD","IE00B775H168.HKD","GDOC","LU0471298777.SGD","LU1145028129.USD","LU1868837136.USD","XLV","LU1093756168.USD","SG9999014914.USD","LU2750360997.AUD","LU2168563687.JPY","LU1548497426.USD","LU0786609619.USD","IE0004445239.USD","LU1917777945.USD","LU0203202063.USD","LU0354030511.USD","LU1069344957.HKD","LU1291159041.SGD","LU0094547139.USD","LU2237443549.SGD","LU0882574139.USD","SG9999015945.SGD","LU2417539215.USD","LU2750360641.GBP","IE00BKVL7J92.USD","BK4581","LU0466842654.USD","IE00BJJMRZ35.SGD","IE00BJLML261.HKD","LU2087625088.SGD","LU2168564495.EUR","JDOC","LU2265009873.SGD","SG9999013999.USD","IE00BFSS7M15.SGD","BK4007","LU2324357040.USD","RXL","LU0079474960.USD","LU2360106947.USD","IE00BFSS8Q28.SGD","LU2896262040.SGD","IE00BKDWB100.SGD","LU0203201768.USD","LU0006306889.USD","LU2236285917.USD","LU0820562030.AUD","LU2471134879.HKD","IE00BWXC8680.SGD","LU1974910355.USD","LU0225283273.USD","THNR","LU1232071149.USD","LU2357305700.SGD","LU2237443895.HKD","IE00B4R5TH58.HKD","LU1551013342.USD","LU0708995401.HKD","LU2264538146.SGD","FTXH","LU2168564222.USD","MEDI","LU0133085943.USD","LU1868837300.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171935778","title":"Paramount Names Kreiz as Co-CEO as Warner Bros. Deal Nears Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=1171935778","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171935778?lang=en_us&edition=fundamental","pubTime":"2026-10-01 07:10","pubTimestamp":1790809815,"startTime":"0","endTime":"0","summary":"David Ellison of Paramount Skydance Corp. said that former Mattel Inc. CEO Ynon Kreiz will become co-CEO of the combined company once the pending $110 billion acquisition of Warner Bros. Discovery...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4108","MMID","PBPH","XLFI","FFSM","CANC","AAUM","PEVC","IYH","VXF","TMED","WMG","PRVT","DFMC","RFG","IEFN","BK4561","BK4571","BK4588","ACTV","GTPE","PSP","IBBQ","RSPH","UYG","BK4585","TBXU","MNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672809747","title":"Regeneron Drug Halves Muscle Loss in Combination with Novo's Semaglutide in Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2672809747","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672809747?lang=en_us&edition=fundamental","pubTime":"2026-10-01 06:01","pubTimestamp":1790805660,"startTime":"0","endTime":"0","summary":"Regeneron drug halves muscle loss in combination with Novo's semaglutide in trialSept 30 (Reuters)-An experimental weight-loss drug being developed by RegeneronREGN.Oused in combination with Novo Nord","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45L14A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU2106854487.HKD","LU0889565916.HKD","LU2237438978.USD","TBXU","LU2324357040.USD","LU2362541273.HKD","LU0114720955.EUR","LU0823416689.USD","LU0320765992.SGD","IBBQ","LU2362540622.SGD","LU2468319806.SGD","LU0289739699.SGD","BBH","BK4585","LU0058720904.USD","BK4588","LU1974910355.USD","LU2023250504.SGD","LU2362541513.USD","BK4139","LU0823434583.USD","REGN","LU0109394709.USD","LU1917777945.USD","IBB","LU2089984988.USD","LU0823434740.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672774782","title":"Gilead Sciences Inc. Stock Underperforms Wednesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2672774782","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672774782?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:35","pubTimestamp":1790800500,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Wednesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slipped 1.47% to $149.05 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 0.25% to 7,651.54 and Dow Jones Industrial Average  falling 0.86% to 50,906.05.This was the stock's second consecutive day of losses.Gilead Sciences Inc. closed 5.24% short of its 52-week high of $157.29, which the company achieved on February 11th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Johnson & Johnson  fell 1.06% to $264.74, Pfizer Inc.  fell 0.70% to $28.52, and Abbott Laboratories  fell 2.10% to $98.83.Data source: Dow Jones Market Data, FactSet. Data compiled September 30, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","LU0823416689.USD","IBB","LU1061106388.HKD","LU0109394709.USD","LU1778281490.HKD","BK4566","LU1571399168.USD","LU1934455863.HKD","LU0320765992.SGD","LU1934455194.USD","LU1674673428.USD","SG9999015952.SGD","BMED","LU1674673691.USD","IE00BSNM7G36.USD","LU1430594728.SGD","TBXU","LU0965509101.SGD","LU1934455277.USD","BK4550","LU0965509283.SGD","LU0889565916.HKD","LU1037948541.HKD","IE00B19Z3B42.SGD","LU2357627491.SGD","LU2112291526.USD","IE00BKVL7J92.USD","IE0002270589.USD","LU2468319806.SGD","BK4585","SG9999015978.USD","BK4139","IE00B19Z3581.USD","LU1057294990.SGD","BK4532","LU1066053197.SGD","LU0882574055.USD","LU0122379950.USD","LU1066051498.USD","BIB","LU2087621335.USD","LU2324357040.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","IE00B3T34201.USD","IE00B7SZLL34.SGD","TMED","LU0058720904.USD","LU1023059063.AUD","LU1037948897.HKD","SG9999015945.SGD","LU0114720955.EUR","LU1585245621.USD","BBH","BK4588","GILD","SG9999015986.USD","LU0965508806.USD","BK4578","MEDI","LU0289739699.SGD","BK4583","LU0861579265.USD","LU0859254822.USD","LU2089984988.USD","IBBQ","BK4568","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672278203","title":"Moderna Inc. Stock Sheds 5.4%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2672278203","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672278203?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:33","pubTimestamp":1790800380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. slipped 5.4% to $192.57 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 0.2% to 26,861.06 and the Dow Jones Industrial Average falling 0.9% to 50,906.05.Moderna Inc. closed 7.8% short of its 52-week high of $208.90, which the company reached on September 29th.The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 1.1% to $264.74, Pfizer Inc. fell 0.7% to $28.52, and Gilead Sciences Inc. fell 1.47% to $149.05.Trading volume totaled 20.1 million, compared to the 50-day average of 19.4 million.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","SG9999015952.SGD","IBB","BK4533","IE00BZ1G4Q59.USD","LU1674673691.USD","GNOM","BMED","BK4566","LU0289739699.SGD","LU1066051498.USD","TMED","LU1066053197.SGD","BK4532","LU2089984988.USD","LU2357627491.SGD","IE0002270589.USD","LU0109394709.USD","LU1778281490.HKD","BK4583","MEDI","LU1057294990.SGD","MRNY","BK4585","BK4139","LU1037948897.HKD","LU0320765992.SGD","IDNA","LU1934455194.USD","GILD","BK4534","LU0058720904.USD","LGHT","MRNX","IE00BSNM7G36.USD","BIB","WDNA","MRNA","LU1430594728.SGD","BBH","IE00B19Z3B42.SGD","BK4568","BK4550","LU1934455863.HKD","SG9999015986.USD","LU1023059063.AUD","SG9999015945.SGD","TBXU","IBBQ","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672078261","title":"Regeneron Links 2026 CEO, CSO PSU Awards to FDA Filings, Approvals and New-Product Revenue Targets Through 2035","url":"https://stock-news.laohu8.com/highlight/detail?id=2672078261","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672078261?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:14","pubTimestamp":1790799285,"startTime":"0","endTime":"0","summary":"Regeneron links 2026 CEO, CSO PSU awards to FDA filings, approvals and new-product revenue targets through 2035Regeneron set 2026 performance stock units for its CEO and CSO with a 10-year performance","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL6RTPN0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU0058720904.USD","LU0823434583.USD","BBH","LU0109394709.USD","REGN","LU2362540622.SGD","LU2023250504.SGD","LU1974910355.USD","LU0823434740.USD","LU0823416689.USD","LU0889565916.HKD","LU2237438978.USD","LU2324357040.USD","LU2362541513.USD","LU2362541273.HKD","BK4588","IBB","BK4585","LU2106854487.HKD","BK4139","TBXU","IBBQ","LU0289739699.SGD","LU1917777945.USD","LU0053666078.USD","LU2468319806.SGD","LU0882574055.USD","LU0320765992.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672784566","title":"Gilead put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2672784566","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672784566?lang=en_us&edition=fundamental","pubTime":"2026-10-01 03:15","pubTimestamp":1790795714,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Gilead (GILD) with 6,354 puts trading, or 4x expected. Most active are Nov-26 140 puts and 10/9 weekly 146 puts, with total v...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BKVL7J92.USD","BIB","IBB","LU0823416689.USD","LU1778281490.HKD","BBH","LU1057294990.SGD","BK4532","BK4578","IE00BSNM7G36.USD","LU1585245621.USD","LU0859254822.USD","LU0114720955.EUR","BMED","LU1066051498.USD","GILD","LU0122379950.USD","LU1430594728.SGD","LU2468319806.SGD","LU0965509283.SGD","TBXU","BK4588","LU0058720904.USD","TMED","LU0965509010.AUD","BK4583","LU2324357040.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","SG9999015945.SGD","LU0234570918.USD","LU1934455863.HKD","IBBQ","LU0889565916.HKD","IE00B3T34201.USD","LU0320765992.SGD","LU2087621335.USD","BK4550","LU1037948897.HKD","LU2112291526.USD","MEDI","SG9999015952.SGD","BK4585","BK4568","SG9999015986.USD","LU1061106388.HKD","LU1839511570.USD","LU2357627491.SGD","LU0882574055.USD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180697906","title":"Lilly's Closely Watched Obesity Combination Therapy Shows Greater Weight Loss in Mid-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1180697906","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180697906?lang=en_us&edition=fundamental","pubTime":"2026-10-01 00:50","pubTimestamp":1790787036,"startTime":"0","endTime":"0","summary":"Key takeaways: Eli Lilly announced that a mid-stage trial in patients with obesity and type 2 diabetes showed its investigational combination therapy produced greater weight loss than high-dose...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","PSYK","IBBQ","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672786096","title":"Regeneron’s ALN-F1202 Safety Trial Marks a Quiet but Important Pipeline Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2672786096","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672786096?lang=en_us&edition=fundamental","pubTime":"2026-10-01 00:30","pubTimestamp":1790785810,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals, Inc. (REGN) has completed a Phase...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regenerons-aln-f1202-safety-trial-marks-a-quiet-but-important-pipeline-milestone?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regenerons-aln-f1202-safety-trial-marks-a-quiet-but-important-pipeline-milestone?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBH","LU0320765992.SGD","LU2106854487.HKD","LU2362540622.SGD","LU2324357040.USD","LU0889565916.HKD","BK4585","ALN","LU0114720955.EUR","LU1974910355.USD","LU2362541513.USD","REGN","LU2023250504.SGD","LU0058720904.USD","LU0823416689.USD","LU2362541273.HKD","IBB","LU0053666078.USD","LU0109394709.USD","IBBQ","BK4588","LU0289739699.SGD","LU0882574055.USD","LU2089984988.USD","LU0823434583.USD","LU2468319806.SGD","TBXU","LU0823434740.USD","LU1917777945.USD","LU2237438978.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124333888","title":"Pre-Holiday Gains: Can This Strong Sector Keep Rising After the Break?","url":"https://stock-news.laohu8.com/highlight/detail?id=1124333888","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124333888?lang=en_us&edition=fundamental","pubTime":"2026-09-30 22:11","pubTimestamp":1790777476,"startTime":"0","endTime":"0","summary":"On September 30, the final trading day before the National Day holiday, A-shares staged a session of \"stable index but internal divergence.\" Throughout the day, the Shanghai Composite Index rose...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IBBQ","BK1574","06978","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193254159","title":"China Pharma Sector Divergence Deepens as Innovative Drug Leaders Ride BD Second Growth Curve","url":"https://stock-news.laohu8.com/highlight/detail?id=1193254159","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193254159?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:30","pubTimestamp":1790775022,"startTime":"0","endTime":"0","summary":"China's pharmaceutical sector is undergoing a structural revaluation.Under the dual pressures of ongoing anti-corruption campaigns and medical insurance cost containment, domestic drugmakers saw...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","159938","09939","06978","IBBQ","BK1574","LNGR","159992","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671520485","title":"MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2671520485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671520485?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:10","pubTimestamp":1790770233,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced that its clinical-stage agenT-797 iNKT platform has been selected as a therapeutic cell system within an Advance...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-selected-for-arpa-h-funded-initiative-to-advance-room-temp-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-selected-for-arpa-h-funded-initiative-to-advance-room-temp-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CNCR","BK4588","LFSC","FBT","BK4585","TBXU","INKT","SYNB","GNOM","IBB","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}